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The Need for Innovative
Sustainable Financing of the
HIV Response
Despite increasing optimism, the end of
AIDS is not in sight. Whereas in 1990,
HIV/AIDS ranked 24th out of the top 25
causes of years of life lost globally, in 2010
it ranked sixth [1]. In 2011, an estimated
1.7 million people died of AIDS-related
causes and 2.5 million were newly infected
with the virus; and the number of people
living with HIV continues to outgrow the
financial and human resources currently
allocated to treat them [2]. While the need
for HIV services increases, health system
constraints limit many countries’ ability to
meet targets for scaling up core HIV
services [2]. Considerable demand-side
barriers remain, as evidenced by the
limited uptake of male circumcision [3].
Structural factors, including poverty, stig-
ma, and gender inequality continue to
underpin HIV vulnerability [4].
Sustainable financing is essential for an
expanded HIV response. UNAIDS has
recently estimated that the cost of achiev-
ing universal access to HIV prevention,
treatment, care, and support in 2015 will
be US$22 billion [5]. Future treatment
costs remain unaddressed with short-term
funding cycles. There is a moral obligation
to maintain treatment for those who need
it, and considerable resources have been
implicitly pre-committed to lifelong HIV
treatment and care. In countries such as
Swaziland and Uganda, the fiscal liability
the commitment to lifelong treatment
creates is substantial—and for the next
two decades may be up to three times
annual gross domestic product (GDP) [6].
Options and Opportunities
Domestic Revenues
In most low- and middle-income coun-
tries, domestic financing is pivotal to
funding the HIV response. While external
financing accounts for two-thirds of HIV
investment in sub-Saharan Africa, more
than two-thirds of general health expen-
diture is financed from domestic sources,
funding the health systems upon which
HIV services rely [7]. However, the
amount of revenue governments can raise
from taxes is constrained due to the risk of
excessive taxation dampening nascent
economic growth. It can therefore be
challenging to identify additional domestic
budgetary flexibility for investments in
HIV, without compromising fiscal stability
[8].
Nevertheless, there is potential from the
positive economic growth and rising
domestic tax revenues forecast in a
number of sub-Saharan African countries
[9]. For example, Zambia’s 5% projected
per capita annual GDP growth rate
between 2011 and 2017 may generate up
to an additional US$21.8 per capita in
health expenditures, based on Zambia’s
current per capita domestic health expen-
diture of US$63.48 [10]. Of course, such
gains will not be possible for all—for
example Swaziland’s 20.1% projected
annual GDP growth rate over the same
period offers limited potential for in-
creased health spending. But, even in
those countries with slow economic
growth, there may be room to increase
tax revenues, with many countries still
being well below the minimum Interna-
tional Monetary Fund (IMF) benchmark
level of 15% of GDP for low-income
countries (see Figure 1) [11]. External
borrowing can also generate revenue,
particularly where there are economic
returns to HIV programmes [12]. How-
ever, for many low-income countries with
high debt-to-GDP ratios, the room to
absorb additional lending remains limited
[8].
External Financing
Economic constraints in high-income
countries appear to be resulting in a flat-
lining of development assistance to health
(DAH) [13]. Non-health development
priorities are dominating the post-2015
agenda for sustainable development, with
only one out of 11 thematic groups
addressing health [14]. Moreover, the
value of providing development assistance
to middle-income countries is being chal-
lenged, leaving some high-prevalence
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countries, such as South Africa, with the
prospect of funding much of their own
HIV response [15].
Much current attention is being placed
on achieving ‘‘value for money.’’ To
avoid resource waste through duplication
and fragmentation [16], DAH needs to be
predictable, aligned to national priorities,
and nationally ‘‘owned,’’ as embodied in
the Paris Declaration on Aid Effective-
ness. The financing for HIV may be
better sustained, planned for, and ab-
sorbed if it becomes part of the broader
shift towards investing in the shared
responsibility for universal coverage of
essential health services [16]. A long term
approach, fully embedded in national
expenditure frameworks, may also reduce
any substitution effect, whereby external
financing replaces domestic financing for
HIV [17].
Tellingly, the United States President’s
Emergency Plan for AIDS Relief (PEP-
FAR) and the Global Fund to Fight AIDS,
Tuberculosis and Malaria (GFATM) are
now emphasising a transition to ‘‘country-
led’’ responses with greater contributions
from domestic sources. PEPFAR now
requires ‘‘cost-sharing assurances’’ of 25%
from governments, while the GFATM
requires between 5% and 60% counterpart
financing, depending on a country’s in-
come classification [18,19]. These require-
ments represent a significant change for
countries like Malawi—where 98% of HIV
spending comes from external sources—
and care has to be taken not to reduce
domestic funding for other essential health
services (Figure 2) as a consequence.
Innovative Financing Sources
Innovative revenue streams are current-
ly being explored in several countries.
These schemes can generate significant
funds, as seen in Zimbabwe with the 3%
AIDS levy deducted from businesses and
formal sector workers’ salaries since 2000
[7]. Other options, such as increased ‘‘sin
taxes’’ on alcohol, could generate a
‘‘double dividend’’ by simultaneously in-
creasing revenues and decreasing HIV-
related risk behaviours [20]. The develop-
ment of social health insurance could help
attract further household resources and
may be an important new source of
financing in middle-income countries as
development assistance scales down [16].
Summary Points
N The financing needs of the HIV response will remain substantial for many years
to come, with current commitments becoming increasingly out of line with
future fiscal liabilities.
N A change in economic approach will be required, drawing on increased
domestic funding, improvements in efficiency, and identification of innovative
new funding streams.
N Organisations providing HIV services must critically examine and justify their
costs and priorities, become increasingly involved in broader health systems
strengthening, and find ways to simultaneously support good governance and
wider development objectives.
N There is need for a renewed economic case to now be made for a reinvigorated
response and a sustainable, long-term national and global financial commit-
ment to ending AIDS.
Figure 1. Growth and taxation rates in low- and lower middle-income countries. Governments’ capacity to generate revenue is higher than
reflected in tax revenue estimates, particularly in oil-producing countries that directly collect profits from oil production. However, most of these
countries had data on tax revenue expressed in percent of non-oil GDP only and were therefore excluded for comparability (e.g., Chad, Republic of
Congo, Gabon, Ghana, Mauritania). The remaining countries where oil was a source of revenue were Cameroon and Cote d’Ivoire, although for the
latter, most of the oil revenue was through taxes (except a small contribution from oil company dividends). Sources: International Monetary Fund
World Economic Outlook Database and Country Reports [32]. Tax revenues are from the latest year available between the five-year period from 2007
to 2011. For Uganda and Madagascar, this meant using the IMF projected estimates for 2007, rather than the actual value, while for Kenya, it meant
using the IMF estimate for 2009–2010. Average annual GDP per capita growth rates (2011–2017) are authors’ calculations from IMF GDP per capita
estimates (in constant prices national currency).
doi:10.1371/journal.pmed.1001567.g001
PLOS Medicine | www.plosmedicine.org 2 December 2013 | Volume 10 | Issue 12 | e1001567
However, none of these options is without
challenges. Earmarking restricts the abil-
ity of governments to allocate funds
efficiently across sectors, and may create
a disincentive to use broader tax revenues
to fund the HIV response. Health
insurance presents considerable chall-
enges in terms of ensuring sustainability,
equity, and financing the care of chronic
illness. Each of these options therefore
needs to be carefully evaluated within the
broader framework of health financing
reform and on a country-by-country
basis.
In addition, between 1990 and 2010,
innovative approaches for raising external
financing for health in low- and middle-
income countries totalled US$6.3 billion,
including solidarity levies from global
taxes (US$970 million, of which US$580
million was from an airline ticket tax) and
funding from novel financing instruments
such as Innovative Financing for Immu-
nisation (US$3.7 billion) [21]. Developing
these approaches and other sources and
the platforms that support them (GAVI,
GFATM, UNITAID, etc.) may offer
further opportunities for greater and more
efficient financing from external sources in
the future [22].
Prioritising Health and HIV
Financing the HIV response must
also be achieved without damaging
investments in health systems more broad-
ly and other development sectors that are
essential for social welfare (in turn ad-
dressing a number of the barriers to
scaling up the HIV response) [5]. An
HIV programme may have important
external benefits for sexual and reproduc-
tive health; maternal and child health; or
provide the necessary health system plat-
forms for managing chronic conditions
[23]. Similarly, investments in strengthen-
ing health systems or addressing related
co-morbidities that compound HIV vul-
nerability or worsen treatment outcomes
are critically important to individuals
living with HIV. Although core HIV
interventions have been demonstrated to
be cost-effective, total HIV spending in
sub-Saharan African countries was an
estimated 19.4% of total health spending
in 2007 (range: 0.7%–64.4%). This
amount exceeds the relative burden of
HIV disability-adjusted life years (DALYs)
[24] and is at least partly due to the
relatively high costs of HIV treatment
compared to treatment for other prevalent
diseases. There remains a difference be-
tween the amount spent on the HIV
response across countries with a similar
GDP per capita and HIV prevalence
(Figure 3), and more work is required to
understand the optimal level of domestic
resourcing for HIV, given competing
health sector priorities.
However, few countries have reached
the Abuja target of a 15% allocation of the
government budget to health (Figure 4)
[16], suggesting that for countries like
Kenya or Mozambique, where the health
sector receives less than 8% of the national
budget, organisations working in HIV
need to work with others to argue for a
re-prioritisation of health more broadly.
Ministries of finance (and donors) can be
reluctant to allocate more resources to the
health sector, when funds remain unspent.
Even with political will, limited capacity to
effectively spend funds in the health sector
can lead to chronic under-spending [25],
further illustrating the importance of
ensuring that key bottlenecks in broader
health systems are fully addressed.
Unfortunately, earmarked external HIV
funds have tended to create a sectoral
‘‘silo’’ mentality, which has led HIV
programmes to miss out on the many
potential synergies within health and with
other development sectors. It is now
critical to take advantage of the wider
benefits generated by some HIV invest-
ments and adopt new co-financing ap-
proaches between HIV and broader
development programmes. For example,
programmes that improve livelihood op-
portunities or help keep young girls in
school may yield HIV as well as develop-
ment benefits [20]. However, at present,
the sector-specific perspectives that
Figure 2. Share of domestic financing in HIV and health expenditures. Countries with the largest numbers of people living with HIV (UNAIDS
2011 estimates) were selected, up until the point where all countries with double-digit HIV prevalence rates were included. Sources: WHO’s Global
Health Expenditure Database [10] and UNAIDS AIDSinfo database [33]. Countries are ordered from lowest to highest adult HIV prevalence (2011
estimates). HIV spending is from the latest year available (2005–2011), while health expenditure data are 2011 estimates.
doi:10.1371/journal.pmed.1001567.g002
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Figure 3. Per capita HIV spending in relation to wealth and disease burden. Countries with the largest numbers of people living with HIV
(UNAIDS 2011 estimates) were selected, up until the point where all countries with double-digit HIV prevalence rates were included. Sources: World
Bank’s World Development Indicators Database [34] and the UNAIDS AIDSinfo database [33]. Adult HIV prevalence and GDP per capita are 2011
estimates, while HIV per capita spending is from the latest year available (2005–2011), but it is unclear from AIDSinfo which currency year is used.
doi:10.1371/journal.pmed.1001567.g003
Figure 4. Prioritisation of health in government expenditures. Sources: WHO’s Global Health Expenditure Database (2011 estimates for
health) [10]. Countries are ordered from lowest to highest adult HIV prevalence (UNAIDS 2011 estimates).
doi:10.1371/journal.pmed.1001567.g004
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dominate priority-setting are not designed
to recognise and harness such opportuni-
ties [26]. Interventions with direct HIV
outcomes may, for example, appear more
attractive than interventions that could
have more structural and long-term ben-
efits for the health or government system
as a whole [27]. Approaches through
which various sectors pool funds or engage
in joint budgeting to fund interventions
with multi-sectoral benefits can be found
in high-income countries [28], and are
worth exploring.
Efficiency Gains within HIV
Programmes
Advocacy pleas for continued funding
for the HIV response will also no longer be
sufficient without parallel demands for
increased efficiency in their use [5].
Improving efficiency is about preventing
more new infections and saving more lives
by doing the right things for the right
populations, as well as delivering quality
services at the lowest cost. The World
Health Organisation (WHO) estimates
that 20%–40% of all resources spent on
health are wasted through leakages, inef-
ficient combinations of interventions, and
sub-optimal use of medicines and human
resources [16]. Good governance is a pre-
requisite given that sustaining financing
from both domestic and external financing
sources is hard to justify when a substantial
leakage of funds exists [29]. Blueprint HIV
programmes may have resulted in ineffi-
ciencies in resource allocation between
different HIV interventions, and left some
highly vulnerable groups under-served
[30]. Increased attention needs to be
placed on prioritising those interventions
with proven effectiveness resulting in the
best patient and population-level outcomes
within the resources available. While there
has been success in recent years in
improving the efficiency of HIV service
providers [2], programme costs still re-
quire careful scrutiny. Reducing the dis-
tortions and duplication inherent in par-
allel management systems [27]—originally
necessary to initiate the rapid scale-up of
HIV services—could help redirect scarce
resources towards direct service delivery.
Improved organisational structures (for
example providing integrated service plat-
forms) and community-based delivery may
also reduce costs to the health system and
patients [5,31], but these gains have yet to
be demonstrated at scale.
Future Policy and Research
Agenda
Adjusting to this new and complex
reality will require a concerted global
effort to support countries to fully institu-
tionalise their response within domestic
governance structures, and move beyond a
silo HIV approach. Domestic finance
ministries, who will increasingly be at the
front-line of the fight against HIV, will
need to be supported with new economic,
epidemiological, and developmental evi-
dence on how to harness each of these
potential areas for increased financing in a
way that reflects their national contexts.
This effort will not be without major
technical, political, and economic chal-
lenges. The magnitude of the conflict
between current commitment levels and
long term fiscal liabilities is substantial.
Increasing domestic financing, improving
efficiency, and adopting a bold and
innovative financing framework will be
central to success. However, none of these
options are easy for governments to
implement. Increasing domestic financing,
particularly in low-income countries, will
require creative solutions to ensure the
poor are not negatively affected. In some
middle-income countries, efforts to in-
crease domestic financing will require a
paradigm shift in the HIV community;
moving away from highlighting resource
needs, towards participating in national
planning processes and offering solutions
that resonate with those working in
broader development policy.
Efforts to improve efficiency will require
impartiality to examine trade-offs from
spending in one area of HIV response
compared to others, some of which may
be unpalatable to different domestic inter-
est groups. HIV programmes will need to
conduct an open, critical examination of
their relative costs compared to other
development programmes. In order for
donors to champion additional external
financing, collaboration, rather than com-
petition, with other development orientat-
ed interest groups will be required. The
relationship between donors and national
governments will need to be carefully
navigated and may become increasingly
complex as governance becomes central to
any offer of co-financing. Finally, the same
level of innovation that has produced some
of the best HIV technologies will now be
required to fund and sustain their use.
To address these challenges there is now
an accentuated need for more and better
evidence that speaks to the needs of
policymakers at the country level. Key
evidence gaps include: better understand-
ing how the HIV response can interact
with the broader health system and other
development sectors; the accurate estima-
tion of the magnitude of the current and
future fiscal commitments and financing
gaps; and evaluating opportunities for
optimising efficiency in service delivery
and new financing modalities. The global
economic crisis and the hope of ending
AIDS do not justify a reduction in our
efforts. Rather, there is need for a renewed
economic case to now be made—along-
side the moral one—for a reinvigorated
response and a sustainable, long-term
national and global commitment to ending
AIDS.
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